SCHEMBL19974868

SCHEMBL19974868

COC(=O)C(C)N(C(C)=O)c1ccccc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.45
TLR9 Q9NR96 1/20 0.45
KMT2A Q03164 3/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
PLA2G1B P04054 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
TSPO P30536 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 3/20 0.39
RAB9A P51151 2/20 0.39
APAF1 O14727 1/20 0.39
TDP2 O95551 1/20 0.39
CASP3 P42574 1/20 0.39
BLM P54132 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21183514 0.86 KMT2A (0.49) PAX8TLR9KMT2AHTTNPSR1
SCHEMBL6138885 0.79 NPSR1 (0.44) KMT2AHTTMEN1PLA2G1BNPSR1
SCHEMBL27373933 0.78 KMT2A (0.50) KMT2AHTTMEN1PLA2G1BNPSR1
SCHEMBL8153694 0.78 KMT2A (0.50) KMT2AHTTMEN1PLA2G1BNPSR1
SCHEMBL2536563 0.75 TSPO (0.67) PAX8TLR9TSPOHPGDRAB9A
SCHEMBL8779567 0.74 KMT2A (0.49) PAX8TLR9KMT2AHTTMEN1
SCHEMBL10481539 0.74 TSPO (0.47) PAX8TLR9TSPOL3MBTL1HPGD
SCHEMBL10874420 0.73 GAA (0.53) PAX8TLR9KMT2AHTTMTNR1A
SCHEMBL29570876 0.73 GAA (0.53) PAX8TLR9KMT2AHTTMTNR1A
SCHEMBL27968718 0.73 KMT2A (0.63) KMT2AHTTMEN1PLA2G1BNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C PAX8 4445/4885TLR9 547/4885KMT2A 4031/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C PAX8 4491/4885TLR9 677/4885KMT2A 4177/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C PAX8 4445/4885TLR9 547/4885KMT2A 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.